Bank of America
BDRX

Bank of America’s Biodexa Pharmaceuticals BDRX Stock Holding History

Bank of America’s Portfolio BDRX Stock Details BDRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1
Closed -$769 – 8170
2024
Q2 		$769 Sell
1
-3
-75% -$3.93K ﹤0.01% 7279
2024
Q1 		$8.48K Hold
4
– – ﹤0.01% 6913
2023
Q4 		$14K Buy
+4
New +$17K ﹤0.01% 6863
2021
Q4 		– Hold
0
– -$1K – 8216
2021
Q3 		– Hold
0
– – – 7962
2017
Q2 		– Hold
0
– – – 6931
2017
Q1 		– Hold
0
– – – 6964

Other funds holding BDRX

UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
CIM
Contravisory Investment Management Norwell, Massachusetts $566M AUM 42.93% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Bank of America's BDRX Position: Q3 2024 in Review

Bank of America sold out of Biodexa Pharmaceuticals (BDRX) in Q3 2024, closing a stake of 1 share — an estimated $769 sold.

Bank of America first reported a position in BDRX in Q4 2023 and held it in 3 quarters. The position peaked at $14K in Q4 2023. 5 funds tracked by Wall St. Rank hold BDRX as of Q3 2024.

  • Bank of America reported no remaining Biodexa Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Bank of America sold 1 Biodexa Pharmaceuticals share in Q3 2024, an estimated $769.
  • Bank of America first reported a position in Biodexa Pharmaceuticals in Q4 2023 and held it in 3 quarters.
  • Bank of America's Biodexa Pharmaceuticals position peaked at $14K in Q4 2023.
  • 5 funds tracked by Wall St. Rank held Biodexa Pharmaceuticals as of Q3 2024.

Based on Bank of America's 13F filing for Q3 2024, filed 14 Nov 2024.